Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SORRY, MY BAD!
Just to be clear, leif, the merger took place on Nov. 11 or 12, with MyMD merging with a newly created subsidiary of AKER so that MyMD is currently a wholly owned subsidiary of AKER.
Totally agree!
About time for MyMD Pharma to get on the stick with some announcements! They have been pretty clear that they will begin the 1st two human studies in the first quarter of 2021 utilizing MYMD-1 against depression in Covid and against Sarcopenia. Only 28 days left in the 1st quarter.
I doubt very much that MyVET Pharma would be associated with the Akers/MyMD Pharma relationship because of the fact that animal meds don't carry the same respectability of human meds. More likely they would be licensed to an existing veterinary pharmaceutical company in exchange for royalties.
Great find that Nemo Life Sciences and Myridine Inc. were just created this month. May have nothing to do with Akers/MyMD, but interesting non the less. Thanks for sharing.
I, personally, am not expecting the Premas connection to amount to anything as we have heard little of any progress lately.
Interesting to note, though, that Supera Pharma and Akers Bio were talking about a merger when MyMD Pharma came on the scene. The plan now is for MyMD Pharma to buy Supera Pharma for about 43 million MyMD shares.
THANKS FOR THE GOOD NEWS!
Mick, what do you think about all this activity.
After AKER/MyMD announced their reverse merger in November a gaggle of law firms jumped on the bandwagon to come to the rescue of AKER stockholders. I'm wondering if maybe they realized it was such a fantastic opportunity for AKER stockholders that they are now providing the share purchasing that is pushing the stock price ever higher!
Hard to believe that no one is commenting on this performance.
You are looking good bono. I'm still betting you are right.
Will continue taking anatabine as long as it is available, but will switch to MYMD-1 if it becomes available as a drug, since it will likely be covered by insurance.
Oops, forgot to mention that in 2021's 1st quarter one of the studies scheduled to begin involves dosing with MYMD-1, post Covid 19 patients who have developed depression, when they previously had not had a problem with it.
Just noticed this story from Jan. 19th that the DOD has hired CRO Pharm-Olam ($36 million) to test Humira against Covid 19 as an inflammation fighter. In the Akers Biosiences Nov. 18 business report, MyMD Chief Scientific Officer, Dr. Adam Kaplan made it pretty clear that MYMD-1 was triple threat superior to Humira in inflammation reduction, anti-depression, and maintenance of immune system.
https://ih.advfn.com/stock-market/stock-news/84120896/us-department-of-defense-selects-pharm-olam-as-cro
Comments welcomed.
Don't know what is going on here, but I think we can thank bonoinvest for getting it moving.
Thanks bono for the update. Will continue to follow until somethings happens.
$2.85 NICER
Someone picked up 2.2 million shares at the close at .0031. Seems like that should have evoked some kind of comment on this board, but maybe I'm the only one left here.
Here's hoping RCPIQ is Jonnie's target for his veterinary venture MyVet Pharmaceuticals Inc. I don't believe he would include it with MyMD Pharmaceuticals for obvious reasons.
mick
Do you have any comment on the the trading in RCPIQ since the Chapter 7 wound up.
Have totally failed to get my head around what they are proposing in this filing with the SEC.
My first reaction, though, is that this filing was known to the insiders ahead of time, and the stock had a great week. I take this as a good sign.
Can't say this is much of a message board, especially since AKER put in quite an impressive performance this week given there was no news to support it. Perhaps the flood of lawyers pursuing AKER for what they think was the lousy deal (80%/20% ownership), discovered that AKER was getting 20% of what may become a mind blowing pharmaceutical powerhouse, and decided to buy into it instead.
Is this a new Akers Biosciences website
http://www.akersbio.com/
Dr Adam Kaplan, who earlier in December officially became the Chief Scientific Officer at MyMD Pharmaceuticals, did an excellent job of detailing the significant advantages of dosing with MYMD-1, in the "Akers Biosciences Business Update".
He points out that it is an excellent selective TNFa blocker which makes it a formidable competetor in the $40 billion market for Humira and other TNFa blockers.
It is also an excellent anti-inflammitory which should be useful in treating any disease or medical condition whose name ends in "itis".
It is also a potent anti-depressant which would have application in countless medical conditions.
All of this comes to the Akers/MyMD merger from MyMD. Akers brings only its questionable relationship with Premas for a vaccine, and its ability to raise funds for MyMD. Thus its 20% share in the final MyMD Pharmaceuticals.
Thanks for posting. Looks like competition heating up for MyMD Pharma/Johns Hopkins. Wonder what the patent situation is!
leifsmith
I have long been aware of the huge pharma forces who want to see MyMD Pharma fail. It is because of this, that as we approach phase 2 human trials, I would like to see MyMD adopt a licensing and royalty approach, whereby any successful phase 2 human study would be licensed to an appropriate international pharmaceutical company for the required phase 3 human study. This would pass on the huge expense of phase 3 studies to companies that can afford it, while making them partners in this new field of medical science.
About your statement "Given the ways of the FDA it may be years before those suffering the effects of chronic inflammation can obtain relief again", I have come to believe that the FDA is fully informed of the significance of the MYMD-1 molecule and will likely fast track it. Only time will tell.
On another note, your mention of izof-texas (eyes of Texas), made me smile as I have been trying to remember his name. He was a big contributor to the anatabine story.
You must have misunderstood my message #30776, if you thought I was saying the merger with AKERS was off! I was just saying that although RCPIQ missed having a merger with MyMD, perhaps RCPIQ will merge one of Jonnie's other companies.
For those of us who were naive enough to hope MYMD Pharma would reverse merge with RCPIQ, the reverse merger with Akers Bio was a big disappointment. However, all is not lost. Jonnie still has MyVET Pharma and SUPERA Pharma and maybe even Revologic Pharma (whatever that is) as potentialy needing a reverse partner. So here goes. Let's keep our fingers crossed!
Looks like AKER has broken out of its trading range of 1.95 to 2.05 on no news at a time of year where tax selling pressure usually predominates. Best of luck to all who have a piece of Akers' Biosciences!
Much thanks for a very thoughtful post. Such posts are a rarity. Interestingly, last Spring when at least 10 countries reported that smokers were significantly underrepresented among those coming to the hospital with Covid, I panicked and ordered 3 bottles of Anatabloc from Pick (knowing I would get 6), because I feared they would discover anatabine could help and it would become unavailable.
No such luck. It was same old, same old! Nicotine was helping smokers, but nicotine was bad bad. Turns out a dozen years ago an intellectually disposed person, snake oil salesman, Jonnie Williams, figured out that nicotinic molecules could do amazing medical things. But the ignorant experts couldn't see it, and many millions of suffering humans have so far been deprived of the benefits of those molecules.
The BID at .0015 is for 1 million shares
misiu
I get my ANATABLOC from Pick Vitamin. They display all of the anatabine products ever sold, but I have only ordered the original Anatabloc lozenges or the Hydrapharm tablets. However, they have always sent me only their own PROFESSIONAL brand tablets, sending me 2 bottles for every bottle I ordered.
The PROFESSIONAL brand seems to be the Hydrapharm tablets.
98% 0f today's 785,000 shares traded went off at .0027 or .0028 in 9 separate trades. Looks suspiciously like accumulation. Can't imagine why anyone would be accumulating !!!!!
Why is someone paying .0028 for a dead stock !!!
"Bankruptcy case closed". RCPIQ trades over 1 million shares, up over 100%. And I thought I had seen it all!!!!!
A search of a number of financial websites shows that most are still showing AKERS outstanding shares as 8.9 million. However, TD Ameritrade shows 18.6 million, indicating recognition of the recent private placement of shares by AKERS.
On the recent "Akers Biosciences Business Update, Joshua Silverman, Lead Independent Director @ AKERS, said "I could say we feel very good about our current cash position with over $36 million and over $2 a share in cash".
This means that even with the very significant dilution of AKERS shares resulting from the more than doubling of shares outstanding, support for AKERS share price still remains at $2.00 a share.
In most respects, leifsmith, I totally agree with you. But as to the FDA letter which removed anatabine from being available, they were correct that anatabine's professed ability to treat disease required that it achieve drug status as required by law. We were on our way with a phase 2 study to demonstrate that anatabine could impact Hashimoto's Thyroiditis when Rock Creek got itself into a funding disaster.
Thanks for the heads-up! Let's see what happens now!
The story here is no longer about Akers Biosystems, it's about MYMD Pharmaceuticals!